Compare IDEXX Laboratories, Inc. (IDXX) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Realty Income Corp — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Realty Income Corp trades at $62.59 (market cap $58.56B). The key difference: Realty Income Corp is the larger of the two by market cap, and Realty Income Corp pays a 5.25% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | O | |
|---|---|---|
Market Cap | $46.22B | $58.56B |
Sector | Health | Real Estate |
52-Week High | $766.68 | $67.56 |
52-Week Low | $526.44 | $55.93 |
Enterprise Value | $47.12B | $89.19B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Realty Income (O) trades at $62.36, up 0.76% with bearish technical signals despite recent earnings misses. The REIT maintains strong fundamentals with $5.75B revenue, 21.23% net margins, and consistent dividend payments. Recent $875M convertible notes offering signals growth ambitions while technical indicators show oversold conditions with RSI at 23.55.
Outlook remains balanced with analyst consensus at $67.29 target (8% upside) despite recent earnings disappointments. Key opportunities include dividend reliability (673 consecutive payments) and data center expansion, while risks involve rising debt levels (39.93% debt-to-asset) and interest rate sensitivity. The stock offers income stability with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
